Neumora Therapeutics (NMRA) Other Gross PP&E Adjustments (2022 - 2026)

Neumora Therapeutics' Other Gross PP&E Adjustments history runs 5 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• In Q1 2026, Other Gross PP&E Adjustments rose 47.25% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$1.5 million (up 47.25% YoY), while the FY2025 annual figure was -$804000.0, up 85.32% from the prior year.
• Other Gross PP&E Adjustments was -$1.5 million for Q1 2026 at Neumora Therapeutics, down from -$804000.0 in the prior quarter.
• In the past five years, Other Gross PP&E Adjustments ranged from a high of -$804000.0 in Q4 2025 to a low of -$9.8 million in Q3 2023.
• Historically, Other Gross PP&E Adjustments has averaged -$4.5 million across 5 years, with a median of -$4.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Gross PP&E Adjustments increased 11.23% in 2023, then soared 85.32% in 2025.
• A 5-year view of Other Gross PP&E Adjustments shows it stood at -$8.8 million in 2022, then climbed by 11.23% to -$7.8 million in 2023, then grew by 29.67% to -$5.5 million in 2024, then jumped by 85.32% to -$804000.0 in 2025, then plunged by 88.43% to -$1.5 million in 2026.
• The last three Other Gross PP&E Adjustments figures came in at -$1.5 million (Q1 2026), -$804000.0 (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.